Hemostasis & Tissue Sealing Agents Market Size Is Poised To Reach USD 14.48 Billion By 2030

Posted by Neha Bora on September 15th, 2022

San Francisco, 15 Sep 2022: The Report Hemostasis & Tissue Sealing Agents Market Size, Share & Trends Analysis Report By Product (Topical Hemostat, Adhesive & Tissue Sealant), By Region (Europe, APAC, North America), And Segment Forecasts, 2022 - 2030

The global hemostasis & tissue sealing agents market size is expected to reach USD 14.48 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.8% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. The rapid growth of minimally invasive technology and the demand for faster recovery by patients are expected to promote market growth over the forecast period.According to the Centers for Disease Control and Prevention (CDC), approximately 150 million of the American population are currently suffering from at least one chronic condition, which leads to surgeries and even mortality at times.

An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer from chronic conditions.The market is expected to witness lucrative growth over the next seven years owing to an increase in product demand supported by the rising surgery volumes. Growth in the geriatric population and the prevalence of chronic conditions are also among the key factorsdriving the market. In December 2019, the Ethicon, a unit of Johnson & Johnson, launched its protein spray for blood-stopping, designed to quickly & efficiently control and seal off excessive bleeding during minimally invasive procedures and open surgeries.

During the COVID-19 pandemic, severe cases among patients infected by the virus have shown the tendency to develop septic shock and Acute Respiratory Distress Syndrome (ARDS), demanding special care in ICU, with residual chronic disability and poor long-term results. Among these patients in the ICU, Coagulopathy has been commonly noticed indicating underlying diseases and organ dysfunction. This has been one of the major contributing factors to the increasing demand for hemostasis & tissue sealing products.

Access Research Report of Hemostasis & Tissue Sealing Agents Market @ https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market

Hemostasis & Tissue Sealing Agents Market Report Highlights

• The market growth can be attributed to a rise in the global volume of surgeries and the applicability of the product across a variety of surgeries to avoid the occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and postoperative complications
• The flowable hemostats segment is expected to witness a lucrative CAGR from 2022 to 2030. Flowable hemostats are a combination of active and mechanical agents
• They function by blocking blood flow and also converting fibrinogen into fibrin for coagulation
• Market participants are involved in technological advancements to ensure sustainability and regional presence
• For instance, in July 2021, Medcura, Inc., a medical devices company, announced the launch of Rapid-Seal, an antibacterial, high-performance hemostatic gel, in partnership with ASO, LLC, a supplier, and manufacturer of first-aid products

List of Key Players of Hemostasis & Tissue Sealing Agents Market

• Johnson & Johnson
• CryoLife, Inc.
• Pfizer
• C R Bard
• B Braun
• Covidien
• Advance Medical Solutions Group
• Smith & Nephew

Access Press Release of Hemostasis & Tissue Sealing Agents Market @ https://www.grandviewresearch.com/press-release/global-hemostasis-tissue-sealing-agents-market